AU2017361253B2 - MAGL inhibitors - Google Patents

MAGL inhibitors Download PDF

Info

Publication number
AU2017361253B2
AU2017361253B2 AU2017361253A AU2017361253A AU2017361253B2 AU 2017361253 B2 AU2017361253 B2 AU 2017361253B2 AU 2017361253 A AU2017361253 A AU 2017361253A AU 2017361253 A AU2017361253 A AU 2017361253A AU 2017361253 B2 AU2017361253 B2 AU 2017361253B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
solvate
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017361253A
Other languages
English (en)
Other versions
AU2017361253A1 (en
Inventor
Daniel J. Buzard
Cheryl A. Grice
Michael B. SHAGHAFI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62145825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2017361253(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of AU2017361253A1 publication Critical patent/AU2017361253A1/en
Assigned to LUNDBECK LA JOLLA RESEARCH CENTER, INC. reassignment LUNDBECK LA JOLLA RESEARCH CENTER, INC. Request for Assignment Assignors: ABIDE THERAPEUTICS, INC.
Assigned to H. LUNDBECK A/S. reassignment H. LUNDBECK A/S. Request for Assignment Assignors: LUNDBECK LA JOLLA RESEARCH CENTER, INC.
Application granted granted Critical
Publication of AU2017361253B2 publication Critical patent/AU2017361253B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2017361253A 2016-11-16 2017-11-15 MAGL inhibitors Ceased AU2017361253B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423102P 2016-11-16 2016-11-16
US62/423,102 2016-11-16
PCT/US2017/061870 WO2018093949A1 (en) 2016-11-16 2017-11-15 Magl inhibitors

Publications (2)

Publication Number Publication Date
AU2017361253A1 AU2017361253A1 (en) 2019-05-30
AU2017361253B2 true AU2017361253B2 (en) 2021-08-05

Family

ID=62145825

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017361253A Ceased AU2017361253B2 (en) 2016-11-16 2017-11-15 MAGL inhibitors

Country Status (27)

Country Link
US (2) US11059822B2 (enExample)
EP (1) EP3541820B1 (enExample)
JP (1) JP7042468B2 (enExample)
KR (1) KR20190080935A (enExample)
CN (1) CN110267962B (enExample)
AU (1) AU2017361253B2 (enExample)
BR (1) BR112019009880A2 (enExample)
CA (1) CA3043617A1 (enExample)
CL (1) CL2019001336A1 (enExample)
CO (1) CO2019004945A2 (enExample)
CR (1) CR20190239A (enExample)
DO (1) DOP2019000118A (enExample)
EA (1) EA038150B1 (enExample)
EC (1) ECSP19034535A (enExample)
ES (1) ES2952582T3 (enExample)
IL (1) IL266547B (enExample)
JO (1) JOP20190107A1 (enExample)
MA (1) MA46855A (enExample)
MX (1) MX389627B (enExample)
NI (1) NI201900049A (enExample)
PE (1) PE20191145A1 (enExample)
PH (1) PH12019501079A1 (enExample)
RU (1) RU2019115784A (enExample)
TN (1) TN2019000149A1 (enExample)
UA (1) UA125523C2 (enExample)
WO (1) WO2018093949A1 (enExample)
ZA (1) ZA201903099B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10781211B2 (en) 2016-05-12 2020-09-22 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
CN110290791A (zh) 2016-11-16 2019-09-27 灵北拉荷亚研究中心公司 药物制剂
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
EP3541807B1 (en) 2016-11-16 2021-09-29 H. Lundbeck A/S A crystalline form of a magl inhibitor
RS64006B1 (sr) 2017-05-23 2023-03-31 H Lundbeck As Pirazol magl inhibitori
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
ES2914363T3 (es) 2017-08-29 2022-06-09 H Lundbeck As Compuestos espirocíclicos y métodos para su preparación y uso
MA50041A (fr) 2017-08-29 2020-07-08 Lundbeck La Jolla Research Center Inc Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
EP3823723A1 (en) * 2018-07-19 2021-05-26 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
HRP20241201T1 (hr) 2018-08-13 2024-11-22 F. Hoffmann - La Roche Ag Novi heterociklički spojevi kao inhibitori monoacilglicerol lipaze
WO2021214550A1 (en) 2020-04-21 2021-10-28 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
UY39516A (es) 2020-11-13 2022-05-31 H Lundbeck As Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión
WO2023130023A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
US12378219B2 (en) 2022-05-04 2025-08-05 H. Lundbeck A/S Crystalline forms of a MAGL inhibitor
WO2024168426A1 (en) 2023-02-13 2024-08-22 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150148330A1 (en) * 2012-01-06 2015-05-28 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
US20160137649A1 (en) * 2013-07-03 2016-05-19 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
WO2016149401A2 (en) * 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
WO2018093946A1 (en) * 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Magl inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1003002A (en) 1910-10-10 1911-09-12 Gustave J Martel Tire-patching device.
MXPA03008109A (es) 2001-03-07 2003-12-12 Pfizer Prod Inc Moduladores de la actividad de receptores de quimiocinas.
EP1948630A2 (en) 2005-11-05 2008-07-30 AstraZeneca AB Novel compounds
WO2008023720A1 (en) 2006-08-23 2008-02-28 Astellas Pharma Inc. Urea compound or salt thereof
CA2716863A1 (en) 2008-03-05 2009-09-11 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
CA2775703C (en) 2009-09-29 2014-07-08 Polyone Corporation Polyester articles having simulated metallic or pearlescent appearance
ES2585806T3 (es) 2009-10-23 2016-10-10 Janssen Pharmaceutica N.V. Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
US9108937B2 (en) 2010-03-04 2015-08-18 Merck Sharp & Dohme Corp. Positive allosteric modulators of mGluR2
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
JP2014005245A (ja) 2012-06-26 2014-01-16 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体を含有する医薬組成物
DK2900669T3 (da) 2012-09-25 2019-11-04 Hoffmann La Roche Hexahydropyrrolo[3,4-C]pyrrolderivater og relaterede forbindelser som autotaxin (ATX)-inhibitorer og som inhibitorer af lysophosphatidsyre (LPA)-produktion til behandling af f.eks. nyresygdomme
AP2016009496A0 (en) 2014-04-04 2016-10-31 X-Rx Inc Substituted spirocydic inhibitors of autotaxin
US10093630B2 (en) 2014-05-21 2018-10-09 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
MX2017014344A (es) 2015-05-11 2018-04-11 Abide Therapeutics Inc Metodos para el tratamiento de la inflacion o el dolor neuropatico.
UA121775C2 (uk) 2015-07-31 2020-07-27 Пфайзер Інк. 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl
US10385057B2 (en) 2015-11-20 2019-08-20 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
ES2822979T3 (es) 2015-11-20 2021-05-05 Lundbeck La Jolla Research Center Inc Derivados de pirazol, procesos para su preparación, y sus usos
ES2804580T3 (es) 2016-03-31 2021-02-08 Takeda Pharmaceuticals Co Compuesto heterocíclico
US10781211B2 (en) 2016-05-12 2020-09-22 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
JOP20190050A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
EP3541807B1 (en) 2016-11-16 2021-09-29 H. Lundbeck A/S A crystalline form of a magl inhibitor
CN110290791A (zh) 2016-11-16 2019-09-27 灵北拉荷亚研究中心公司 药物制剂
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
US10350205B2 (en) 2017-03-13 2019-07-16 Abide Therapeutics, Inc. Dual MAGL and FAAH inhibitors
RS64006B1 (sr) 2017-05-23 2023-03-31 H Lundbeck As Pirazol magl inhibitori
JOP20190267A1 (ar) 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
MA50041A (fr) 2017-08-29 2020-07-08 Lundbeck La Jolla Research Center Inc Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
ES2914363T3 (es) 2017-08-29 2022-06-09 H Lundbeck As Compuestos espirocíclicos y métodos para su preparación y uso
UY39516A (es) 2020-11-13 2022-05-31 H Lundbeck As Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150148330A1 (en) * 2012-01-06 2015-05-28 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
US20160137649A1 (en) * 2013-07-03 2016-05-19 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
WO2016149401A2 (en) * 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
WO2018093946A1 (en) * 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Magl inhibitors

Also Published As

Publication number Publication date
MA46855A (fr) 2021-05-19
JP2020500178A (ja) 2020-01-09
UA125523C2 (uk) 2022-04-13
US20200291023A1 (en) 2020-09-17
WO2018093949A1 (en) 2018-05-24
CN110267962A (zh) 2019-09-20
EP3541820B1 (en) 2023-07-05
US11691975B2 (en) 2023-07-04
CL2019001336A1 (es) 2019-10-04
JOP20190107A1 (ar) 2019-05-09
EP3541820A1 (en) 2019-09-25
NZ753471A (en) 2021-01-29
IL266547A (en) 2019-07-31
CO2019004945A2 (es) 2019-05-21
MX2019005773A (es) 2019-12-05
US20220135563A1 (en) 2022-05-05
TN2019000149A1 (en) 2020-10-05
MX389627B (es) 2025-03-20
RU2019115784A (ru) 2020-12-17
PH12019501079A1 (en) 2019-08-19
AU2017361253A1 (en) 2019-05-30
RU2019115784A3 (enExample) 2021-03-12
ES2952582T3 (es) 2023-11-02
PE20191145A1 (es) 2019-09-02
NI201900049A (es) 2019-10-30
CN110267962B (zh) 2022-04-01
BR112019009880A2 (pt) 2019-08-13
DOP2019000118A (es) 2019-09-30
JP7042468B2 (ja) 2022-03-28
US11059822B2 (en) 2021-07-13
CA3043617A1 (en) 2018-05-24
IL266547B (en) 2022-06-01
EP3541820A4 (en) 2020-06-10
ZA201903099B (en) 2021-01-27
KR20190080935A (ko) 2019-07-08
ECSP19034535A (es) 2019-05-31
EA038150B1 (ru) 2021-07-14
EA201991029A1 (ru) 2019-12-30
EP3541820C0 (en) 2023-07-05
CR20190239A (es) 2019-06-26

Similar Documents

Publication Publication Date Title
AU2017361253B2 (en) MAGL inhibitors
AU2017361251B2 (en) MAGL inhibitors
EP3675848B1 (en) Spirocycle compounds and methods of making and using same
US9981930B1 (en) MAGL inhibitors
AU2018236161B9 (en) Dual MAGL and FAAH inhibitors
EP3515897A1 (en) Piperazine carbamates and methods of making and using same
HK40009161B (en) Magl inhibitors
HK40009161A (en) Magl inhibitors
NZ753471B2 (en) Magl inhibitors
NZ753264B2 (en) Magl inhibitors
HK40032870B (en) Spirocycle compounds and methods of making and using same
HK40032870A (en) Spirocycle compounds and methods of making and using same

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: H. LUNDBECK A/S.

Free format text: FORMER APPLICANT(S): LUNDBECK LA JOLLA RESEARCH CENTER, INC.

Owner name: LUNDBECK LA JOLLA RESEARCH CENTER, INC.

Free format text: FORMER APPLICANT(S): ABIDE THERAPEUTICS, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired